Cointime

Optimer Pharmaceuticals

company

About

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing

  • 251 - 500

Highlights

Total Funding Amount
$22.20M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series D
Last Funding Money Raised
$22.20M
Industries
Biotechnology,Health Care,Pharmaceutical,Therapeutics
Founded date
Jan 1, 1998
Number Of Employee
251 - 500
Operating Status
Close

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$22.20M
Optimer Pharmaceuticals has raised a total of $22.20M in funding over 2 rounds. Their latest funding was raised on Dec 14, 2005 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 14, 2005 Series D $22.20M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Optimer Pharmaceuticals is funded by 1 investors. SB Life Science are the most recent investors.
Investor Name Lead Investor Funding Round
SB Life Science — Series D
Cointime
เนื้อหา
บริษัท